The performance of hepatocyte-targeted magnetic resonance (MR) contrast agents in the detection of liver tumor was tested in rats with hepatitis. Hepatocyte-targeted MR contrast agents (paramagnetic hepatobiliary complex [manganese-DPDP] and superparamagnetic iron oxide coated with arabinogalactan [SPIO-AG]) were injected into normal rats and rats with carbon tetrachloride-induced hepatitis. Before and after injection of either contrast agent, ex vivo relaxometry (0.94T) or in vivo MR imaging (1.0T) were performed. The obtained liver and tumor T 1 and T 2 relaxation times, liver and tumor signal-to-noise ratios (SNR), and tumor-liver contrast-to-noise ratios (CNR) of control rats and rats with hepatitis were compared.
Introduction
DiŠuse liver diseases often mask liver cancer in ultrasound, CT (computed tomography), and MR (magnetic resonance) images [1] [2] [3] [4] [5] because the echo level, density, and relaxation times of cancerous tissues overlap those of in‰ammatory processes. 6, 7 Hepatocyte-targeted pharmaceuticals can provide a mechanism for distinguishing cancer from the surrounding liver. 8 Paramagnetic and superparamagnetic contrast agents developed for MR imaging have shown enhanced tumor-liver contrast in normal animals. [9] [10] [11] Hepatitis was expected to reduce the uptake of hepatocyte-targeted contrast agents. 12, 13 If contrast agent uptake depends upon hepatocyte function, reduced uptake in areas of hepatitis would resemble tumorous tissue. Focal hepatitis would mimic cancer and diŠuse hepatitis would mask cancer. However, if the uptake and enhancement of contrast agents is not aŠected by hepatocellular injury, these contrast agents could improve the detection of liver cancer despite the presence of hepatitis. To investigate the diagnostic e‹cacy of hepatocyte-targeted MR contrast agents, we have developed an animal model of liver cancer associated with hepatocellular injury.
Materials and Methods

Contrast agents
The hepatobiliary paramagnetic complex, manganese-dipyridoxal diphosphate (MnDPDP from Salutar Inc., now is available as Teslascan [mangafodipir trisodium] from GE Healthcare). The magnetic, biologic, and toxicological properties of this material have been reported in earlier studies, and the dosage of 15 mmol W kg has been chosen for experimental use. [14] [15] [16] This material is selectively taken up via the cell membrane transport system in the liver and excreted into the biliary system. 14, 15 As tested in our laboratory, the longitudinal (r1) and transverse relaxivities (r2) of MnDPDP are 2.3 and 4.0 (s
), respectively, in a 1z agar gel at 0.94T.
The superparamagnetic iron oxide particles (SPIO-AG) were obtained from Advanced Magnetics Inc., Cambridge, MA, USA. The particles are coated with arabinogalactan and targeted at the asialoglycoprotein receptor on the hepatocytes. The mean diameter of the particles is 12 nm. 13, 17, 18 The magnetic, biologic, and toxicological properties and eŠective dosage (10 mmol W kg) of this material have already been reported. 13, 17, 18 As tested in our laboratory, the r1 and r2 of SPIO-AG are 21 and 86 (s
Animal preparation
Female Sprague-Dawley rats (Charles River Breeders, Wilmington, MA, USA) weighing 300-400 g were used in this study. Rat mammary carcinosarcoma (Walker 256, Biomeasure Inc., Hopkinton, MA, USA) was directly implanted into the liver according to previously described methods. [19] [20] [21] The rats were studied for 7-8 days after tumor implantation, when the tumor size reached a diameter of 0.5-1 cm. CCl4 was selected as a wellcharacterized, reproducible, and widely available model of hepatocellular injury. Twenty four hours prior to study, 21 tumor-bearing animals were administered 0.4 ml W kg of a 1:1 mixture of carbon tetrachloride (CCl4) in corn oil via gastric intubation to induce chemical hepatitis. 4, 22 Tumor-bearing animals with or without hepatitis were studied before and after contrast administration. Mn-DPDP or SPIO-AG was injected via tail vein and the animals were studied 30 min or 60 min after contrast administration, respectively.
Ex vivo relaxometry
The longitudinal (T1) and transverse (T2) relaxation times were measured with a 0.94T MR spectrometer (PC-140 Minispec; Bruker, Milton, ON, Canada) at 409 C. T1 was measured by means of a least-squaresˆt to eight data points generated with an inversion recovery pulse sequence. T2 was measured from 10 data points generated by a CarrPurcell-Meiboom-Gill pulse sequence. The T1 and T2 relaxation times of liver and tumor tissue were measured from 14 tumor-bearing animals with hepatitis and 12 tumor-bearing controls without hepatitis.
The enhancement attributable to the magneto- Signal intensities were measured by operatordeˆned regions of interest (greater than 50 pixels) of the tumor, liver, and background noise oŠset in the frequency encoding direction to avoid ghost artifacts. 23 The signal-to-noise ratio (SNR) and the tumor-liver contrast-to-noise ratio (CNR) were calculated with standard methods (SNR＝Signal W SDnoise; CNR＝[Stumor-Sliver] W SDnoise). [23] [24] [25] [26] For quantitative comparison of SNR and CNR data acquired with diŠerent pulse sequences, SNR and CNR values were normalized to scanning times and slice thickness with standard techniques. 27, 28 The signiˆcance of the diŠerences between the SNR and CNR in controls and animals with hepatitis was evaluated with the unpaired t-test.
Results
Ex vivo relaxometry
In the absence of any contrast agent, liver T1 and T2 relaxation times were signiˆcantly (Pº0.01) increased after administration of CCl4 (Table) . The liver T1 and T2 showed a mean 16z increase (from 432±17 to 499±34 ms) and a mean 31z increase (from 40.9±2.1 to 53.4±4.4 ms). The tumor T1 and T2 relaxation times were not changed by CCl4-induced hepatitis. The diŠerence between the tumor and liver T1 relaxation rates ( D1 W T1) was ). These results indicate that chemical hepatitis reduces the inherent relaxation rate diŠerence (contrast) between the tumor and surrounding liver (Fig. 1) .
MnDPDP: Injection of MnDPDP signiˆcantly decreased (Pº0.01) the liver T1 and T2 relaxation times in both controls and animals with hepatitis (Table) . The liver T1 in controls and in animals with hepatitis showed a mean 126z decrease (from 432±17 to 191±4 ms) and a mean 143z decrease (from 499±34 to 205±19 ms) with MnDPDP, respectively. MnDPDP increased the diŠerence between the tumor and liver T1 relaxation rate ( D1 W T1) by a mean of 134z in controls (from 1.21± ; Pº0.01, Fig. 1 ). SPIO-AG: Injection of SPIO-AG signiˆcantly (Pº0.01) decreased the liver T1 and T2 relaxation times in both controls and animals with hepatitis (Table) . The liver T1 in controls and in animals with hepatitis showed a mean 37z decrease (from 40.9 ±2.7 to 25.9±3.0 ms) and a mean 54z decrease (from 53.4±4.4 to 24.7±2.5 ms) with SPIO-AG, respectively. SPIO-AG increased the diŠerence between the tumor and liver T2 relaxation rate ( D1 W T2) by a mean of 129z in controls (from 12.7 ±1.5 s ; Pº0.01, Fig. 1 ).
In vivo MR imaging
The unenhanced liver SNRs and tumor SNRs in animals with hepatitis were not signiˆcantly diŠer-ent from those in the controls in the SE 310 W 15 images (Figs. 2A, B) . Similarly, the tumor-liver CNRs in unenhanced T1-weighted SE 310 W 15 images showed no signiˆcant diŠerence (PÀ0.05) between control animals and animals with hepatitis (Figs. 3, 4) . The unenhanced liver SNRs were signiˆcantly diŠerent from those in controls in Fig. 2A) , but the tumor SNRs were unchanged. As a result, the tumor-liver CNRs in animals with hepatitis were signiˆcantly smaller (Pº0.05) than those in the controls in T2-weighted SE 2000 W 45 and 2000 W 90 images (Figs. 3, 5) .
MnDPDP: The liver SNRs in the SE 310 W 15 images were signiˆcantly increased (Pº0.05) in both controls and animals with hepatitis 30 min after MnDPDP injection ( Fig. 2A) . Tumor enhancement with MnDPDP slightly increased the tumor SNRs, but to a lesser degree than the increase in the liver SNRs (Fig. 2B) . The tumor-liver CNRs in the SE 310 W 15 images were signiˆcantly increased (Pº0.05) by MnDPDP injection in the controls from -3.1±0.2 to -10.4±3.6 (235z) and increased from -4.1±0.7 to -11.5±1.4 (180z) in animals with hepatitis. The MnDPDP-enhanced tumor-liver CNRs in controls (-10.4±3.6) and in were not signiˆcantly diŠerent (Figs. 3, 5) .
Discussion
Our experimental model of liver cancer in the presence of chemical hepatitis resembles liver cancer occurring in alcoholics and in those with viral hepatitis and is therefore well suited for contrast media research in MR imaging. The model is simple, easy reproducible, and inexpensive and contains no risk of potential viral contamination. 29 Our results show that acute hepatitis does not prevent liver-speciˆc relaxation enhancement by hepatocyte-targeted magnetopharmaceuticals. Thiŝ nding contradicts published expectations that the uptake of hepatocyte-targeted contrast agents would be decreased in the presence of hepatitis. 12, 13 It has been documented that injured livers show sustained liver enhancement with MnDPDP. 30, 31 Previous expectations that a contrast agent could be used to detect cancer (by enhancing liver) [9] [10] [11] 18 and distinguish normal liver from hepatitis (by not enhancing liver) 12, 13 are somewhat contradictory. This study conˆrms that MnDPDP and SPIO-AG maintain cancer detection despite the presence of hepatitis.
Possible explanations for the preservation of liver-speciˆc enhancement in the presence of hepatocellular injury are as follows: First, the biodistribution of the drug might not be changed at all, because the uptake mechanisms are not aŠected by the hepatic injury; second, the normal uptake mechanisms are impaired in hepatic injury, but the liver might have an alternative mechanism for drug uptake; third, while the uptake might be reduced, relaxivity might be increased in the altered intracellular environment;ˆnally, it should be augured that the echo time used in T1-weighted SE 310 W 15 images may be too long to diŠerentiate between normal and injured livers. 30 Theˆrst explanation might account for the enhancement with MnDPDP in hepatitis. It is not fully understood whether the uptake mechanism of MnDPDP is energy-dependent and whether it is the same as that of pyridoxal 5? phosphate (PLP) or that of free manganese ions. In humans, it has been shown that the plasma clearance of PLP is increased in acute hepatitis. 32 Evidence also exists that energy-independent processes allow the uptake of a substantial amount of Mn 2＋ in the injured liver. 33 The second explanation of an alternative uptake mechanism might account for the unchanged enhancement by SPIO-AG in hepatitis. It is known that galactose-bearing particles are taken up by hepatocytes via receptor-mediated endocytosis, an energy-dependent process that could be impaired in hepatic injury. If the uptake by hepatocytes were decreased, the unchanged liver uptake of SPIO-AG in hepatitis might be explained by the increased phagocytic activity of the KupŠer cells. KupŠer cells are also thought to have asialoglycoprotein receptor activity. 34 For the third explanation, decreased but diŠuse biodistribution of phagocytosed SPIO in the injured liver would play an important role in sustaining contrast enhancement. 35, 36 Finally, pulse sequences with shorter echo times might produce diŠerent results, and this explanation could be applied only to in vivo MR imaging data. Further studies will be needed to investigate the mechanisms of uptake and the enhancement of hepatocyte-targeted MR contrast agents.
Conclusion
The two hepatocyte-targeted contrast agents, MnDPDP and SPIO-AG, both increased tumorliver CNRs in the presence of hepatitis to the same degree as in the controls.
